GlaxoSmithKline

Global biopharmaceutical major GlaxoSmithKline (GSK) has launched a new portfolio of oncology therapies in India, specifically designed to address gynaecological cancers such as ovarian and endometrial malignancies. The move underscores GSK’s strategy to strengthen its presence in the oncology segment while expanding treatment options for patients who have limited access to advanced therapies.

GlaxoSmithKline Pharmaceuticals (GSK India) reported a robust financial performance for the March quarter, with a 36% increase in consolidated net profit to Rs. 263 crore, compared to Rs. 194 crore in the previous year. The company’s revenue from operations also rose to Rs. 974 crore in Q4, up from Rs. 930 crore last year. For the fiscal year ending March 31, 2025, GSK’s net profit soared to Rs. 927 crore, reflecting a significant jump from Rs. 590 crore in FY24.